This substantial financial boost, backed by both new and existing investors, marks a significant milestone for the company as it looks to improve the landscape of microbiome therapeutics.

The funding round was made up of £15.7m in equity funding, as well as the conversion of £11.6m in loan notes into equity. 

The round saw contributions from seasoned life science investors Thairm Bio and Kineticos Life Sciences, alongside the Scottish National Investment Bank (SNIB). Additionally, existing investors such as Scottish Enterprise and several private investors reaffirmed their commitment.

At the forefront of EnteroBiotix’s agenda with the new funding is the advancement of its lead product candidate, EBX-102-02, through a Phase 2 clinical trial targeting Irritable Bowel Syndrome (IBS) in collaboration with the Functional Gut Clinic. 

Beyond IBS, the company aims to expand its pipeline to address other conditions associated with disruptions in the gut microbiome, including liver cirrhosis and hepatic encephalopathy (HE).

“This significant new investment helps enable our vision of transforming the standard of care for patients suffering from serious conditions linked to the gut microbiome. It will help accelerate the development of our innovative product pipeline and propels us towards our goal of bringing these innovative treatments to market,” said Dr James McIlroy, CEO of EnteroBiotix.

“We look forward to working closely with our new partners at the Bank and with our existing investors to bring this vision to fruition, for the benefit of patients across the globe.”

Recommended reading

• Scots Dental Biotech Firm Secures £5M Funding Boost
• Biotech Funding Levels-up IBioIC’s Scale-up Facility
• Biotech Sector Gets £100M in New Funding From UK Government

EnteroBiotix’s endeavours could impact the medical landscape, offering hope for improved treatments and outcomes for patients grappling with gastrointestinal disorders and associated complications. 

According to Statista, the share of adults diagnosed with gastrointestinal conditions in the US is about 22%, a number which jumps to 44% when self reporting.